PRIME is an EU-funded project (H2020-EU.3.1.1. – Understanding health, wellbeing and disease) and states that insulin signalling not only affects the body (e.g., diabetes and obesity) but also the brain (e.g., Alzheimer’s disease, autism and obsessive-compulsive disorders). The multidisciplinary PRIME consortium aims to better understand this body-brain co-morbidity and will bring this acquired knowledge to society (e.g., medication, lifestyle interventions, medical guidelines and policy). Furthermore, educational approaches to inform clinicians, patients, and general public will be developed. The project kicked off in January 2020 and will last 5 years.